medigraphic.com

2014, Number 4

<< Back Next >>

Cir Cir 2014; 82 (4)

New guidelines in regard to cervical cancer screening

Vargas-Hernández VM, Acosta-Altamirano G, Moreno-Eutimio MA, Vargas-Aguilar VM

Language: Spanish
References: 27
Page: 453-459
PDF size: 342.64 Kb.


ABSTRACT

Cancer screening programs have been successful in reducing the incidence and mortality due to cervical cancer. For more than a decade, the human papillomavirus test has been recommended as part of these programs, however, Pap tests is not currently recommended for women ‹21 years of age or in those with total hysterectomy for benign disease, unrelated to cancer or precursor lesions of malignant diseases. This is because most of the anomalies observed in adolescents regress spontaneously, and cytological screening tests for this age group cause unnecessary anxiety, additional testing and, therefore, a higher cost. Moreover, there is little evidence that cytology is useful in women after hysterectomy, finding that outcomes are not improved. In women ›65 years of age who participated adequately in screening programs, continuing with these screening programs is not needed. Screening programs will be different in special populations at greatest risk where tests are frequently needed or use of alternative methods.


REFERENCES

  1. Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006;4:13.

  2. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62(3):147-172.

  3. Karjane N, Chelmow D. New cervical cancer screening guidelines, again. Obstet Gynecol Clin North Am 2013;40(2):211-223.

  4. Bishop A, Wells E, Sherris J, Tsu V, Crook B. Cervical cancer: Evolving prevention strategies for developing countries. Reproductive Health Matters 1995;3(6):60-71.

  5. Lazcano-Ponce EC, Moss S, Alonso de Ruiz P, Salmeron- Castro J, Hernandez-Avila M. Cervical Cancer Screening in Developing Countries: Why Is it Ineffective? The Case of Mexico. ArchMed Res 1999;30(3):240-250.

  6. Vargas-Hernández VM, Acosta-Altamirano G. Rendimiento de la citología cervicouterina en la era de la biología molecular. Rev EnferTract Genit Inf 2011;5(1):11-14.

  7. Vargas-Hernández VM, Vargas-Carriche C, Cruz-Martinez J. Métodos de detección de cáncer cervico uterino. En Vargas-Hernández VM, editor. Cáncer en la Mujer, Edit. Alfil, México, 2011. p. 537-545.

  8. Gustafsson L, Pontén J, Bergstrôm R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997;71(2):159-165.

  9. Gustafsson L, Pontén J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8(5):755-763.

  10. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-S25.

  11. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19.

  12. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer; a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11(11):1048-1056.

  13. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348(6):518-527.

  14. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348(6):489-490.

  15. Castle PE, Fetterman B, Cox JT, Shaber R, Poitras N, Lorey T, et al. The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer. Obstet Gynecol 2010;116(1):76-84.

  16. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188(6):1383-1392.

  17. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al, Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis. J Natl Cancer Inst 2003;95(1):46-52.

  18. Wright TC Jr. Cervical Cancer Screening in the 21st Century. Is it Time to Retire the PAP smear? Clin Obstet Gynecol 2007;50(2):313-323.

  19. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011;20(7):1398-1409.

  20. Vargas-Hernández VM, Acosta-Altamirano G. Prevención primaria del cáncer cervicouterino. Cir Cir 2012;80(3):291- 279.

  21. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: Systematic review and metaanalysis. Prev Med 2007;45(2-3):93-106.

  22. Scarinci IC, Garcia FAR, Kobetz E, Partridge EE, Brandt HM, Bell MC, et al. Cervical cancer prevention. New tools and old barriers. Cancer 2010;116(11):2531-2542.

  23. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, de la Rosa AP, Witlen R. Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective. Salud Publica Mex 2008;50(2):107-118.

  24. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61(34):671-677.

  25. Kably-Ambe A, Ruiz-Moreno JA, Ponce EL, Vargas- Hernández VM, Aguado-Pérez RA, Alonso de Ruiz P, et al. Consensus for the prevention of cervical cancer in Mexico. Ginecol Obstet Mex 2011;79(12):785-787.

  26. Darus CJ, Mueller JJ. Development and impact of Human Papillomavirus Vaccines. Clin Obstet Gynecol 2013;56(1):10-16.

  27. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 200;58(RR-4):1-207.




2020     |     www.medigraphic.com